SCHEMBL2377159

SCHEMBL2377159

CCN(CC)CCSc1ccc(C=CC(=O)OC)cc1N

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 15/20 0.76
HDAC3 O15379 3/20 0.50
HDAC4 P56524 3/20 0.50
HDAC1 Q13547 3/20 0.50
HDAC7 Q8WUI4 3/20 0.50
HDAC2 Q92769 3/20 0.50
HDAC10 Q969S8 3/20 0.50
HDAC11 Q96DB2 3/20 0.50
HDAC8 Q9BY41 3/20 0.50
HDAC9 Q9UKV0 3/20 0.50
HDAC5 Q9UQL6 3/20 0.50
TTR P02766 1/20 0.44
APP P05067 1/20 0.44
PTPN1 P18031 1/20 0.42
BCHE P06276 2/20 0.42
ACHE P22303 2/20 0.42
FDPS P14324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2377156 1.00 HDAC6 (0.76) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL12243818 0.86 HDAC6 (1.00) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL2376456 0.86 HDAC6 (1.00) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL2376709 0.83 HDAC6 (0.78) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL2376704 0.83 HDAC6 (0.78) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL833494 0.78 HDAC6 (0.47) HDAC6TTRAPPPTPN1BCHE
SCHEMBL833493 0.78 HDAC6 (0.47) HDAC6TTRAPPPTPN1BCHE
SCHEMBL2377251 0.77 HDAC6 (0.81) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL2377248 0.77 HDAC6 (0.81) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL29913987 0.73 APP (0.73) HDAC6HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921424-B2 Histone deacetylase inhibitors, process for preparation and uses thereof ZHEJIANG HISUN PHARMACEUTICAL CO. LTD. (CN) 2014-12-30 US disclosed
EP-2208721-B1 HISTONE DEACETYLASE INHIBITOR, COMPOSITION AND USE THEREOF ZHEJIANG HISUN PHARM CO LTD (CN) 2013-12-25 EP disclosed
US-20110218221-A1 NOVEL HISTONE DEACETYLASE INHIBITORS, PROCESS FOR PREPARATION AND USES THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2011-09-08 US disclosed
EP-2208721-A1 HISTONE DEACETYLASE INHIBITOR, COMPOSITION AND USE THEREOF Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218221-A1 NOVEL HISTONE DEACETYLASE INHIBITORS, PROCESS FOR PREPARATION AND USES THEREOF HDAC1, HDAC5, HDAC11 HDAC6 11/4885HDAC3 10/4885HDAC4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.